Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 3Triple Negative Breast Neoplasms 2Melanoma 2Unilateral Breast Neoplasms 1Resectable Esophageal Cancer 1Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioblastoma 1Ganglioneuroblastoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Temozolomide 41Radiotherapy 19Radiation 12Nivolumab 10pembrolizumab 8Magnetic Resonance Spectroscopy 8Bevacizumab 7Specimen Handling 6poly ICLC 4atezolizumab 4Lomustine 4Ipilimumab 4Surgical Procedures, Operative 3Photons 3Immunoglobulin G 3Disulfides 3Cyclophosphamide 3veliparib 2sargramostim 2rocakinogene sifuplasmid 2olaparib 2niraparib 2Transurethral Resection of Bladder 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2OKN 007 2Mycophenolic Acid 2Metformin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Glioblastoma × Colony-Stimulating Factors × Clear all
NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Roswell Park Cancer Institute

Phase 2 Active not recruiting
66 enrolled 11 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡